NASDAQ$LYRA
Lyra Therapeutics Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Lyra Therapeutics reported financial results and highlighted recent accomplishments.
Lyra Therapeutics reported a net loss of $11.0 million for the second quarter of 2021. The company's cash and cash equivalents were $69.0 million as of June 30, 2021, and they expect it to fund operations into 2023. They also announced a licensing agreement with LianBio for LYR-210 and have a clear path forward to advance LYR-210 into Phase 3 clinical development.
- Successful EOP2 FDA meeting for LYR-210 in CRS, with Phase 3 program on track to begin around year-end 2021.
- Entered into a licensing agreement with LianBio for LYR-210 in Greater China and other Asian markets.
- Reported positive topline results from an LYR-210 PK study, supporting a 505(b)(2) NDA pathway.
- Cash and cash equivalents were $69.0 million as of June 30, 2021, expected to fund operations into 2023.
Headline financials
Revenue & EPS history
Lyra · Revenue · Quarterly
$25K
Revenue by segment
Lyra · $410K total across 1 segment · Q1 2023
- Collaboration revenue$410K—100.0%
Forward guidance
Lyra Therapeutics expects to advance LYR-210 into Phase 3 clinical development for the treatment of Chronic Rhinosinusitis around year-end. LYR-220 for post-surgical CRS patients, is also advancing and remains on track to enter Phase 2 later this year.
Tailwinds
- Clear path forward to advance LYR-210 into Phase 3 clinical development for the treatment of Chronic Rhinosinusitis.
- LYR-220 for post-surgical CRS patients is advancing and remains on track to enter Phase 2 later this year.
- LYR-210 and LYR-220 will disrupt the current CRS treatment landscape.
- Provide a new pharmacologic solution for the full spectrum of the 4 million U.S. CRS patients who fail medical management each year.
- Cash balance to be sufficient to fund its planned operations into 2023.
Headwinds
- Incurred significant losses since inception and expects to incur losses for the foreseeable future.
- Need for additional funding, which may not be available.
- Limited operating history.
- No approved products.
- Product candidates are in various stages of development.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
-1.6%
Avg return
Earnings day
-3.1%
Avg return
5 days after
-1.7%
Avg return
30 days after
29%
7 / 24 earnings
Positive
+11.0%
Q1 2024
Best reaction
-25.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +0.0% | +0.1% | +52.2% | |
| Q3 2025 | -1.0% | -5.9% | -6.3% | |
| Q2 2025 | +9.5% | +8.3% | -6.8% | |
| Q1 2025 | -6.3% | -17.3% | +102.9% | |
| Q4 2024 | -4.1% | -14.8% | -39.2% | |
| Q3 2024 | -25.4% | -35.8% | -23.8% | |
| Q2 2024 | -3.3% | +4.0% | -6.6% | |
| Q1 2024 | +11.0% | -14.8% | -93.0% | |
| Q4 2023 | +2.8% | +1.0% | -14.5% | |
| Q3 2023 | +0.0% | +2.4% | +33.4% | |
| Q2 2023 | +5.4% | +13.8% | +20.8% | |
| Q1 2023 | -6.8% | -2.1% | +3.6% | |
| Q4 2022 | +6.1% | +13.8% | +22.4% | |
| Q3 2022 | -17.9% | -20.3% | -35.8% | |
| Q2 2022 | -1.7% | +0.6% | -5.2% | |
| Q1 2022 | +7.1% | +7.7% | +18.1% | |
| Q4 2021 | -4.0% | -5.8% | +22.8% | |
| Q3 2021 | -1.0% | -0.4% | -32.9% | |
| Q2 2021 | -3.9% | -0.4% | +17.6% | |
| Q1 2021 | -1.0% | -5.6% | +11.9% | |
| Q4 2020 | -4.8% | -2.2% | -20.9% | |
| Q3 2020 | +1.0% | -1.8% | -13.3% | |
| Q2 2020 | -0.9% | +0.9% | -17.8% | |
| Q1 2020 | -0.5% | +0.1% | -31.6% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro